MétaCan
Menu
← Back to cohort

Abstract 15684: Adherence and Persistence to SGLT2 Inhibitors in Patients With Heart Failure

2023· article· en· W4389958644 on OpenAlexaffabout
Shogo Kono, Jungyeon Moon, Alice Chong, Jiming Fang, Dennis T. Ko, Peter C. Austin, Clare Atzema, David Naimark, Jacob A. Udell, Thérèse A. Stukel, Karen Tu, Gillian L. Booth, Cynthia A. Jackevicius

Bibliographic record

VenueCirculation · 2023
Typearticle
Languageen
FieldMedicine
TopicDiabetes Treatment and Management
Canadian institutionsUniversity of TorontoSunnybrook Health Science CentreInstitute for Clinical Evaluative Sciences
Fundersnot available
KeywordsMedicineEmpagliflozinPersistence (discontinuity)DapagliflozinMedical prescriptionDiabetes mellitusCumulative incidenceInternal medicineCohortCanagliflozinHeart failurePopulationRetrospective cohort studyIncidence (geometry)Medication adherenceCohort studyIntensive care medicineEmergency medicineType 2 diabetesPharmacologyEndocrinologyEnvironmental health

Abstract

fetched live from OpenAlex

Introduction: While originally used solely as antihyperglycemic agents, sodium-glucose cotransporter 2 inhibitors (SGLT2i) are now recommended for use in heart failure (HF) to reduce hospitalization and cardiovascular mortality. Unfortunately, benefits of treatment can only be fully realized if a patient is adherent to therapy. While SGLT2i adherence has been found to be suboptimal in diabetes populations, SGLT2i adherence has not been well-studied in patients with HF. Since medication non-adherence in HF tends to be high in general, and can lead to worse clinical outcomes, this study aimed to estimate SGLT2i adherence/persistence rates in a population-based cohort of HF patients. Methods: This retrospective cohort study included patients ≥65 years discharged alive from a hospital in Ontario, Canada between 4/2016 and 3/2021, who had a primary diagnosis of HF and were dispensed a SGLT2i prescription. Prescription claims were used to identify and calculate 6-month and 1-year SGLT2i adherence and 1-year persistence, from the first date of fill for an SGLT2i. Adherence was calculated as the proportion of days covered (PDC), with PDC≥80% defined as “good” adherence. Persistence was calculated with a “permissible” gap of 30 days allowed before being considered non-persistent. A cumulative incidence function was utilized to account for the competing risk of death in persistence calculations. Results: There were 5,257 eligible patients (59% male, mean age 76.94±7 years, 73.8% with diabetes), for whom empagliflozin (64.9%), dapagliflozin (25.5%) and canagliflozin (9.5%) were used. The overall mean PDC was 83.9% at 6-months and 80.5% at 1-year, with the proportion of patients with “good” adherence (PDC≥80%) at 76.2% and 72.5%, respectively. Persistence to all prescribed SGLT2i was 71.3% at 1-year, with highest persistence with dapagliflozin at 74.4% and lowest persistence with canagliflozin at 68.1% [p=0.01]. Conclusion: In this HF cohort on SGLT2i, nearly 3 out of 4 patients were highly adherent and persistent at one year. SGLT2i adherence/persistence rates are higher than seen in studies in diabetes populations. Further studies are needed to identify those at risk of non-adherence/non-persistence and to examine association with clinical outcomes.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.002
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.114
Threshold uncertainty score0.226

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0010.002
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0010.001
Science and technology studies0.0010.000
Scholarly communication0.0010.000
Open science0.0000.000
Research integrity0.0000.001
Insufficient payload (model declined to judge)0.0020.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.017
GPT teacher head0.232
Teacher spread0.215 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations2
Published2023
Admission routes2
Has abstractyes

Explore more

Same venueCirculation→Same topicDiabetes Treatment and Management→French-language works237,207→